Silvestre Jean-Sébastien
Paris-Cardiovascular Research Center-Inserm U970, Hôpital européen Georges Pompidou, 56, rue Leblanc, 75015 Paris, France.
Med Sci (Paris). 2009 Nov;25(11):931-8. doi: 10.1051/medsci/20092511931.
The application of endothelial progenitor cells (EPC) cell-based therapy for regenerative medicine constitutes a promising therapeutic avenue for the treatment of cardiovascular diseases. Based on experimental studies demonstrating that bone marrow-, blood- or tissue-derived stem/progenitor cells improve the functional recovery after ischemia, clinical trials were initiated to address this new therapeutic concept. Although autolougous cell therapy was shown to improve perfusion and function of ischemic tissues, a number of issues remain to be adressed. The nature of the mobilizing, migratory and homing signals, and the mechanisms of action need to be identified and further defined. In addition, strategies to enhance homing, survival and therapeutic potential of EPC need to be developped to improve therapeutic effect and counteract EPC dysfunction in aged patients with cardiovascular risk factors. The present review article will discuss the mechanisms of action of different types of adult stem cells and several approaches to improve their therapeutic efficiency.
基于内皮祖细胞（EPC）的细胞疗法在再生医学中的应用为心血管疾病的治疗构成了一条前景广阔的治疗途径。基于实验研究表明，骨髓、血液或组织来源的干/祖细胞可改善缺血后的功能恢复，于是开展了临床试验以探讨这一新的治疗理念。尽管自体细胞疗法已被证明可改善缺血组织的灌注和功能，但仍有一些问题有待解决。需要识别并进一步明确动员、迁移和归巢信号的性质以及作用机制。此外，需要制定策略来增强EPC的归巢、存活和治疗潜力，以提高治疗效果并对抗有心血管危险因素的老年患者的EPC功能障碍。本综述文章将讨论不同类型成体干细胞的作用机制以及几种提高其治疗效率的方法。
